Intravenous nicorandil cut the risk of periprocedural myocardial injury (pMI) after percutaneous coronary intervention (PCI) by 49 percent among patients 65 and older, according to a substudy of a randomized trial published in PLOS One. The initial trial showed a nonsignificant decline in biomarker release and pMI among patients who received nicorandil or remote ischemic preconditioning (RIPC) when compared to a control group. However, lead author Norifumi Kawakita and colleagues predicted they could show a more significant impact of the interventions among older patients.

Read More